Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PTPRA | P18433 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL555036 | 1.00 | MAPT (0.50) | MAPTSMN1; SMN2HTTDNM1LMNA | |
| SCHEMBL239274 | 1.00 | MAPT (0.50) | MAPTSMN1; SMN2HTTDNM1LMNA | |
| Hydrochloric Acid SCHEMBL1140275 | 0.98 | MAPT (0.49) | MAPTSMN1; SMN2HTTDNM1LMNA | |
| Hydrochloric Acid SCHEMBL6422363 | 0.98 | MAPT (0.49) | MAPTSMN1; SMN2HTTDNM1LMNA | |
| Phosphoric Acid SCHEMBL8362755 | 0.85 | MAPT (0.43) | MAPTSMN1; SMN2HTTDNM1LMNA | |
| SCHEMBL5514976 | 0.83 | MAPT (0.48) | MAPTSMN1; SMN2HTTDNM1LMNA | |
| SCHEMBL12227832 | 0.82 | FDPS (0.54) | SMN1; SMN2HTTLMNAKDM4EPTPRA | |
| SCHEMBL14157786 | 0.82 | MAPT (0.44) | MAPTHTTLMNAKDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL4829746 | 0.81 | MAPT (0.42) | MAPTHTTLMNAKDM4EMEN1 | |
| SCHEMBL6086624 | 0.81 | MAPT (0.57) | MAPTSMN1; SMN2HTTDNM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633326-B2 | Method for preparing taxane derivatives | SAMYANG BIOPHARMACEUTICALS CORPORATION (KR) | 2014-01-21 | — | — | US | claimed |
| US-20120035379-A1 | METHOD FOR PREPARING TAXANE DERIVATIVES | SAMYANG GENEX CORPORATION (KR) | 2012-02-09 | — | — | US | claimed |
| WO-2010123186-A1 | METHOD FOR PREPARING TAXANE DERIVATIVES | SAMYANG GENEX CORPORATION (KR) | 2010-10-28 | — | — | WO | claimed |
| US-6130336-A | Process for preparing paclitaxel | HANMI PHARM., CO. LTD. (KR) | 2000-10-10 | — | — | US | claimed |
| EP-0923565-A1 | PROCESS FOR PREPARING PACLITAXEL | HANMI PHARMACEUTICAL CO.,LTD. (KR) | 1999-06-23 | — | — | EP | claimed |
| WO-1998008832-A1 | PROCESS FOR PREPARING PACLITAXEL | HANMI PHARM. CO., LTD. (KR) | 1998-03-05 | — | — | WO | claimed |
| JP-1305076-A | — | — | None | — | — | JP | disclosed |
| US-20260041775-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS, LLC (US) | 2026-02-12 | — | — | US | disclosed |
| US-11173209-B2 | Compositions for drug administration | AEGIS THERAPEUTICS, LLC (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210121573-A1 | ABSORPTION ENHANCERS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS, LLC | 2021-04-29 | — | — | US | disclosed |
| US-20200138956-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS, LLC | 2020-05-07 | — | — | US | disclosed |
| US-10265402-B2 | Absorption enhancers for drug administration | AEGIS THERAPEUTICS, LLC (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180221489-A1 | ABSORPTION ENHANCERS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS, LLC | 2018-08-09 | — | — | US | disclosed |
| WO-1996040667-A1 | PACLITAXEL SYNTHESIS FROM PRECURSOR COMPOUNDS AND METHODS OF PRODUCING THE SAME | NAPRO BIOTHERAPEUTICS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040666-A1 | PACLITAXEL SYNTHESIS FROM PRECURSOR COMPOUNDS AND METHODS OF PRODUCING THE SAME | NAPRO BIOTHERAPEUTICS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996013495-A1 | TAXOID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1996-05-09 | — | — | WO | disclosed |
| EP-0681568-A1 | PROCESS FOR PREPARATION OF TAXANE DERIVATIVES AND $g(b)-LACTAM INTERMEDIATES THEREFOR | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1995-11-15 | — | — | EP | disclosed |
| WO-1994018164-A1 | PROCESS FOR PREPARATION OF TAXANE DERIVATIVES AND β-LACTAM INTERMEDIATES THEREFOR | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1994-08-18 | — | — | WO | disclosed |
| US-5294737-A | Hydrolysis, cyclization, condensation | THE RESEARCH FOUNDATION STATE UNIVERSITY OF NEW YORK (US) | 1994-03-15 | — | — | US | disclosed |
| JP-H01305076-A | METHOD FOR PREPARING TAXOL | CENTRE NATL RECH SCIENT <CNRS> | 1989-12-08 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11173209-B2 | Compositions for drug administration | SLC10A1, ABCB11, CSGALNACT1 | MAPT 2171/4885SMN1; SMN2 1045/4885HTT 593/4885 |
| US-20120035379-A1 | METHOD FOR PREPARING TAXANE DERIVATIVES | PTMA, TNPO3, ACR | MAPT 737/4885SMN1; SMN2 2678/4885HTT 2862/4885 |
| US-20260041775-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | SLC2A8, SLC5A2, SLC2A4 | MAPT 452/4885SMN1; SMN2 1656/4885HTT 1113/4885 |
| US-20200138956-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | SLC10A1, ABCB11, CSGALNACT1 | MAPT 2171/4885SMN1; SMN2 1045/4885HTT 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.